Literature DB >> 28468588

A herpes simplex virus type 2-encoded microRNA promotes tumor cell metastasis by targeting suppressor of cytokine signaling 2 in lung cancer.

Xudong Wang1, Shupeng Liu2, Zhenhua Zhou1, Hongli Yan2, Jianru Xiao1.   

Abstract

Certain viruses use microRNAs to regulate the expression of their own genes, host genes, or both. A number of microRNAs expressed by herpes simplex virus type 2 have been confirmed by previous studies. However, whether these microRNAs play a role in the metastasis of lung cancers and how these viral microRNAs precisely regulated the tumor biological process in lung cancer bone metastasis remain obscure. We recently identified the high expression of an acutely and latently expressed viral microRNA, Hsv2-miR-H9-5p, encoded by herpes simplex virus type 2 latency-associated transcript through microarray and quantitative polymerase chain reaction analyses which compared the expression of microRNAs in bone metastasis from lung cancer with primary lung cancers. We now reported that Hsv2-miR-H9-5p was highly expressed in bone metastasis and closely associated with pathological and metastatic processes of lung cancers. The functions of Hsv2-miR-H9-5p were determined by overexpression which results in an increase in survival, migration, and invasion of lung cancer cells in vitro. We determined that Hsv2-miR-H9-5p directly targeted SOCS2 mechanistically by dual-luciferase reporter assay. Then, we investigated the functions of SOCS2 in the progress of lung cancers. Reduction of SOCS2 dosage by hsv2-miR-H9-5p induced increased migration and invasion of lung cancer cells. Overexpression of SOCS2 inverted these phenotypes generated by hsv2-miR-H9-5p, indicating the potential roles of SOCS2 in Hsv2-miR-H9-5p-driven metastasis in lung cancers. The results highlighted that Hsv2-miR-H9-5p regulated and contributed to bone metastasis of lung cancers. We proposed that Hsv2-miR-H9-5p could be used as a potential target in lung cancer therapy.

Entities:  

Keywords:  Hsv2-miR-H9-5p; SOCS2; bone metastasis; lung cancer

Mesh:

Substances:

Year:  2017        PMID: 28468588     DOI: 10.1177/1010428317701633

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

Review 1.  Immunomodulatory roles of human herpesvirus-encoded microRNA in host-virus interaction.

Authors:  Afsar R Naqvi
Journal:  Rev Med Virol       Date:  2019-08-20       Impact factor: 6.989

Review 2.  SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis.

Authors:  Christine I Alston; Richard D Dix
Journal:  Front Immunol       Date:  2019-04-11       Impact factor: 7.561

3.  Profiling of tRNA Halves and YRNA Fragments in Serum and Tissue From Oral Squamous Cell Carcinoma Patients Identify Key Role of 5' tRNA-Val-CAC-2-1 Half.

Authors:  Joseph Dhahbi; Yury O Nunez Lopez; Augusto Schneider; Berta Victoria; Tatiana Saccon; Krish Bharat; Thaddeus McClatchey; Hani Atamna; Wojciech Scierski; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak
Journal:  Front Oncol       Date:  2019-09-26       Impact factor: 6.244

Review 4.  SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses.

Authors:  Shanzhi Huang; Ke Liu; Anchun Cheng; Mingshu Wang; Min Cui; Juan Huang; Dekang Zhu; Shun Chen; Mafeng Liu; Xinxin Zhao; Yin Wu; Qiao Yang; Shaqiu Zhang; Xumin Ou; Sai Mao; Qun Gao; Yanling Yu; Bin Tian; Yunya Liu; Ling Zhang; Zhongqiong Yin; Bo Jing; Xiaoyue Chen; Renyong Jia
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

5.  miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2).

Authors:  Yanhong Tu; Fan Mei
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 6.  The Emerging Role of Non-Coding RNAs in the Regulation of Virus Replication and Resultant Cellular Pathologies.

Authors:  Soudeh Ghafouri-Fard; Bashdar Mahmud Hussen; Hazha Hadayat Jamal; Mohammad Taheri; Guive Sharifi
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.